The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
(2017) · Institute for Social Research eBooks · doi:10.3998/2027.42/139710 · Cited by 1,364
European Monitoring Centre for Drugs and Drug Addiction
Anderson, M. (2014) · European Union regulations | European Encyclopedia of law · Cited by 1,213
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“More recently, LSD and psilocybin have been evaluated in pilot therapeutic studies as treatments for anxiety in patients with life-threatening diseases (11,27).”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 2×
“To date, brain activation patterns have not been studied using LSD in neuroimaging studies, in contrast to several modern investigations that used psilocybin to model psychotic states (25,26).”
BackgroundResultGating and Habituation of the Startle Reflex in Schizophrenic Patients
Braff, D. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820030038005 · Cited by 1,027
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“Serotoninergic hallucinogens, including LSD, are hypothesized to act at the 5-HT2A receptor (2,54), which is upregulated in patients with schizophrenia (72).”
BackgroundSelf-citationMartin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 943
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 7×
“More recently, LSD and psilocybin have been evaluated in pilot therapeutic studies as treatments for anxiety in patients with life-threatening diseases (11,27).”
BackgroundMethodInfluentialSelf-citationThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 1×
“In particular, LSD produced 30% higher ratings for oceanic boundlessness (mostly blissful state), 30% higher ratings for anxious ego dissolution, and 63% higher ratings for visionary restructuralization (mostly greater audiovisual synesthesia) compared with a high dose of psilocybin (55,57).”
BackgroundSelf-citationPsychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 2×
“Compared with DMT and ketamine, LSD produced 50% higher ratings for oceanic boundlessness, 50% higher ratings for visionary restructuralization, and comparably high ratings for anxious ego dissolution (22,29).”
BackgroundMethodSelf-citationLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · cited 1×
“” It has also been investigated for the treatment of alcoholism (6), addiction (7), cluster headache (8), and anxiety associated with terminal illness (9–11).”
BackgroundThe Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451 · cited 7×
“In particular, LSD produced 30% higher ratings for oceanic boundlessness (mostly blissful state), 30% higher ratings for anxious ego dissolution, and 63% higher ratings for visionary restructuralization (mostly greater audiovisual synesthesia) compared with a high dose of psilocybin (55,57).”
BackgroundInfluentialVollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · cited 2×
“To date, brain activation patterns have not been studied using LSD in neuroimaging studies, in contrast to several modern investigations that used psilocybin to model psychotic states (25,26).”
BackgroundResultSelf-citationSerotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427
Self-citationPrediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
Self-citationGender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
Self-citationMDMA enhances emotional empathy and prosocial behavior
Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quednow, B. B., & Liechti, M. E. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst161 · Cited by 356
Self-citationVollenweider, F. X., Leenders, K. L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00039-9 · Cited by 353
Self-citationTiteler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343 · cited 1×
“Pharmacologically, LSD acts as a direct partial agonist at serotoninergic receptors (2,63), whereas MDMA mostly acts as an indirect serotoninergic agonist by releasing serotonin via the serotonin transporter (64).”
BackgroundLSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320 · cited 1×
“Despite the widespread recreational use, no experimental scientific pharmacologic studies have been conducted with LSD in the last 40 years, until recently (14).”
BackgroundPharmacokinetics of Hoasca alkaloids in healthy humans
Callaway, J. C., McKenna, D. J., Grob, C. S., Brito, G. S., Raymon, L. P., Poland, R. E., Andrade, E. N., Andrade, E. O., & Mash, D. C. (1999) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(98)00168-8 · Cited by 315
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291
Monitoring the future. Building an early warning system for the Dutch Ministry of Justice
Botterhuis, L., van der Duin, P., de Ruijter, P., & van Wijck, P. (2010) · Futures · doi:10.1016/j.futures.2009.11.030 · Cited by 290
Response of cluster headache to psilocybin and LSD
Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006) · Neurology · doi:10.1212/01.wnl.0000219761.05466.43 · Cited by 259
Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00126-3 · Cited by 245 · cited 1×
“MDMA produces weak LSD-like perceptual alterations, likely via similar 5-hydroxytryptamine 2A (5-HT2A) receptor stimulation (62).”
BackgroundSelf-citationDeficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia
Ludewig, K., Geyer, M. A., & Vollenweider, F. X. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01925-x · Cited by 240
Self-citationVarty, G. B., Higgins, G. A., & Higgins, G. A. (1995) · Psychopharmacology · doi:10.1007/bf02246437 · Cited by 231
Quednow, B. B., Kometer, M., Geyer, M. A., & Vollenweider, F. X. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.228 · Cited by 230
Self-citationLSD-Assisted Psychotherapy in Patients with Terminal Cancer
Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (2017) · International Pharmacopsychiatry · doi:10.1159/000467984 · Cited by 209
Kumari, V. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.609 · Cited by 208
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., & Kovar, K.-A. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-916185 · Cited by 198
Vollenweider, F. X., Csomor, P. A., Knappe, B., Geyer, M. A., & Quednow, B. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301324 · Cited by 190
Self-citationHysek, C. M., Simmler, L. D., Nicola, V. G., Vischer, N., Donzelli, M., Krähenbühl, S., Grouzmann, E., Huwyler, J., Hoener, M. C., & Liechti, M. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036476 · Cited by 178
Self-citationThe Psychopharmacology of Hallucinogens
Abraham, H., Aldridge, A. M., & Gogia, P. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00136-2 · Cited by 172
Hysek, C. M., Simmler, L. D., Ineichen, M., Grouzmann, E., Hoener, M. C., Brenneisen, R., Huwyler, J., & Liechti, M. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.78 · Cited by 166
Self-citationSANTOS, R. G. D., Valle, M., Bouso, J. C., Nomdedeu, J. F., Rodríguez-Espinosa, J., McIlhenny, E. H., Barker, S. A., Barbanoj, M. J., & Riba, J. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823607f6 · Cited by 164
Hill, H. E., Haertzen, C. A., Wolbach, A. B., & Miner, E. J. (1963) · Psychopharmacologia · doi:10.1007/bf02584089 · Cited by 159
Gouzoulis‐Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, H. J., Kovar, K. ‐., Lindenblatt, H., Hermle, L., Spitzer, M., & Sass, H. (1999) · Psychopharmacology · doi:10.1007/s002130050860 · Cited by 157
Differential effects of MDMA and methylphenidate on social cognition
Schmid, Y., Hysek, C. M., Simmler, L. D., Crockett, M. J., Quednow, B. B., & Liechti, M. E. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114542454 · Cited by 155 · cited 1×
“Similar subjective effects are typically produced by empathogens, such as MDMA, but not by stimulants (30,60).”
BackgroundSelf-citation(1969) · PubMed · Cited by 150
Residential Psychedelic (LSD) Therapy for the Narcotic Addict: A Controlled Study
Savage, C. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750360040005 · Cited by 148 · cited 1×
“” It has also been investigated for the treatment of alcoholism (6), addiction (7), cluster headache (8), and anxiety associated with terminal illness (9–11).”
BackgroundHysek, C. M., Simmler, L. D., Schillinger, N., Meyer, N., Schmid, Y., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001132 · Cited by 145
Self-citationMDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions
Hysek, C. M., Domes, G., & Liechti, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2645-9 · Cited by 144
Self-citationImpaired Sensorimotor Gating of the Acoustic Startle Response in the Prodrome of Schizophrenia
Quednow, B. B., Frommann, I., Berning, J., Kühn, K.-U., Maier, W., & Wagner, M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.019 · Cited by 141
Comparison of the reactions induced by psilocybin and LSD-25 in man
Isbell, H. (1959) · Psychopharmacology · doi:10.1007/bf00408109 · Cited by 140
Ramos, L., Hicks, C., Kevin, R., Caminer, A., Narlawar, R., Kassiou, M., & McGregor, I. S. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.125 · Cited by 128 · cited 13×
“Feelings of well-being, happiness, closeness to others, openness, and trust were also increased by LSD, effects typically associated with the empathogen MDMA (Ecstasy) (52).”
BackgroundInfluentialBelleville, R. E., Fraser, H. F., Isbell, H., LOGAN, C. R., & Wikler, A. (1956) · PubMed · Cited by 126
DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum
Sipes, T. E., & Geyer, M. A. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00316-8 · Cited by 119
Farré, M., Abanades, S., Roset, P. N., Peiró, A. M., Torrens, M., O'Mathúna, B., Segura, M., & de la Torre, R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129056 · Cited by 117
Ouagazzal, A., Grottick, A. J., Moreau, J., & Higgins, G. A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00282-2 · Cited by 116
Hofmann, A. (1979) · Journal of Psychedelic Drugs · doi:10.1080/02791072.1979.10472092 · Cited by 110
Isbell, H. (1956) · A M A Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1956.02330290012002 · Cited by 110
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995) · Psychopharmacology · doi:10.1007/bf02245940 · Cited by 107
Seifritz, E., Baumann, P., Müller, M. J., Annen, O., Amey, M., Hemmeter, U., Hatzinger, M., Chardon, F., & Holsboer-Trachsler, E. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00117-v · Cited by 105
Krebs-Thomson, K., Ruiz, E. M., Masten, V. L., Buell, M. R., & Geyer, M. A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0566-1 · Cited by 97
Coma, Hyperthermia, and Bleeding Associated with Massive LSD Overdose a Report of Eight Cases
Klock, J., Boerner, U., & Becker, C. E. (1975) · Clinical Toxicology · doi:10.3109/15563657508988063 · Cited by 83
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
Halberstadt, A. L., & Geyer, M. A. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1718-x · Cited by 81
Serotonergic hallucinogens as translational models relevant to schizophrenia
Halberstadt, A. L., & Geyer, M. A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000722 · Cited by 81
Gouzoulis‐Mayfrank, E., Heekeren, K., Thelen, B., Lindenblatt, H., Kovar, K. ‐., Sass, H., & Geyer, M. A. (1998) · Behavioural Pharmacology · doi:10.1097/00008877-199811000-00011 · Cited by 80
LYSERGIC ACID DIETHYLAMIDE AND RELATED SUBSTANCES
Rothlin, E. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40756.x · Cited by 80
Riba, J., Rodríguez‐Fornells, A., & Barbanoj, M. J. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1237-5 · Cited by 79
Hollister, L. E., & Hartman, A. M. (1962) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(62)80024-8 · Cited by 78
Quednow, B. B., Schmechtig, A., Ettinger, U., Petrovsky, N., Collier, D. A., Vollenweider, F. X., Wagner, M., & Kumari, V. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.007 · Cited by 72
Self-citationEXPERIMENTAL PHYSIOLOGICAL STUDIES WITH LYSERGIC ACID DIETHYLAMIDE (LSD-25)
Forrer, G. R., & GOLDNER, R. D. (1951) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1951.02320050038004 · Cited by 66
Gouzoulis‐Mayfrank, E., Habermeyer, E., Hermle, L., Steinmeyer, A., Kunert, H. J., & Sass, H. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80686-5 · Cited by 63
Páleníček, T., Hlinak, Z., Bubeníková‐Valešová, V., Novák, T., & Horáček, J. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.02.008 · Cited by 62
THE EFFECTS OF D‐LYSERGIC ACID DIETHYLAMIDE ON CEREBRAL CIRCULATION AND OVER‐ALL METABOLISM
Sokoloff, L., Perlin, S., Kornetsky, C. H., & Kety, S. S. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40742.x · Cited by 58
Seibert, J., Hysek, C. M., Penno, C. A., Schmid, Y., Kratschmar, D. V., Liechti, M. E., & Odermatt, A. (2014) · Neuroendocrinology · doi:10.1159/000364879 · Cited by 52
Self-citationGiacomelli, S., Palmery, M., Romanelli, L., Cheng, C. Y., & Silvestrini, B. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00262-8 · Cited by 50
Heekeren, K., Neukirch, A., Daumann, J., Stoll, M., Obradovic, M., Kovar, K. ‐., Geyer, M. A., & Gouzoulis‐Mayfrank, E. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077734 · Cited by 50
LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND SCHIZOPHRENIC REACTIONS
LANGS, R. J., & Barr, H. L. (1968) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196808000-00008 · Cited by 46
Model Psychoses Induced by LSD-25 in Normals
Bercel, N. A. (1956) · A M A Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1956.02330240026003 · Cited by 35
Mescaline: the chemistry and pharmacology of its analogs.
Shulgin, A. T. (1973) · PubMed · Cited by 33
Acute and chronic LSD effects on rat startle: data supporting an LSD--rat model of schizophrenia.
Dl, B., & Geyer, M. A. (1980) · PubMed · Cited by 32
Progression of Effects of Lysergic Acid Diethylamide [LSD]
Salvatore, S., & HYDE, R. W. (1956) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1956.02330250052007 · Cited by 31
Lysergic acid diethylamide: Evidence for stimulation of pituitary dopamine receptors
Meltzer, H. Y., Fessler, R. G., Simonovic, M., Doherty, J. D., & Fang, V. S. (1977) · Psychopharmacology · doi:10.1007/bf00426539 · Cited by 25
Kupferschmidt, K. (2014) · Science · doi:10.1126/science.345.6192.18 · Cited by 24
The Pharmacology of Mescaline and D-Lysergic Acid Diethylamide (LSD)
Koelle, G. B. (1958) · New England Journal of Medicine · doi:10.1056/nejm195801022580106 · Cited by 18
Methodological Issues of Human Experimental Research with Hallucinogens
Gouzoulis‐Mayfrank, E., Schneider, F. W., Friedrich, J., Spitzer, M., Thelen, B., & Sass, H. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979356 · Cited by 16
Sommers, K. D., van Wyk, M., & Snyman, J. R. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00191908 · Cited by 14
A STUDY OF THE EFFECTS OF L.S.D.: PHYSIOLOGIC AND PSYCHOLOGICAL CHANGES AND THEIR INTERRELATIONS
DiMascio, A., Greenblatt, M., & Hyde, R. W. (1957) · American Journal of Psychiatry · doi:10.1176/ajp.114.4.309 · Cited by 12
Relation of Physiological and Psychological Effects of Lysergic Acid Diethylamide
Kornetsky, C. H. (1957) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1957.02330360115013 · Cited by 10
Research works printed but not linked: 4
- Stoll, 1947, Lysergsäureäthylamid, ein Phantastikum aus der Mutterkorngruppe, Schweiz Arch Neurol Psychiatr, 60, 279
- Janke, 1978, Die Eigenschaftswörterliste, Göttingen: Hogrefe
- Dimascio, 1957, A study of the effects of L.S.D.: Physiologic and psychological changes and their interrelations, Am J Psychiatry, 114, 309, 10.1176/ajp.114.4.309 · DOI
- Horita, 1954, Pyretogenic effect of lysergic acid diethylamide, Science, 120, 1100, 10.1126/science.120.3131.1100 · doi:10.1126/science.120.3131.1100
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706
Metadata
- Authors
- Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 78
- Issue
- 8
- Pages
- 544-553
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2109884356
- Cited by
- 411
- References
- 90
- FWCI
- 30.38
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- University Hospital Basel, Switzerland
- Swiss National Science Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.